AHK-Cu tripeptide-copper complex stimulates human hair follicle elongation and dermal papilla cell proliferation ex vivo
Background
Hair loss affects millions globally, yet pharmacological options remain limited and mechanistically narrow. Dermal papilla cells (DPCs) are specialized fibroblasts that orchestrate hair follicle morphogenesis and cycling; their proliferation and survival are rate-limiting for follicle growth. The tripeptide-copper complex AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu²⁺) was already known to act as a growth factor for differentiated cells, stimulating dermal fibroblast proliferation and elevating VEGF secretion while suppressing TGF-β1 — a cytokine linked to follicle miniaturization. Whether these fibroblast-targeted effects extend specifically to DPCs and translate into measurable hair-shaft elongation had not been tested.
Study Design
Human hair follicles were cultured ex vivo and treated with AHK-Cu at 10⁻¹²–10⁻⁹ M to assess elongation as the primary endpoint. Isolated human DPCs were exposed to the same dose range in vitro to measure proliferation. Apoptosis was quantified via Annexin V-FITC/PI labeling with flow cytometric analysis. Expression of apoptosis regulators was assessed by measuring the Bcl-2/Bax ratio and the cleaved forms of caspase-3 and PARP at 10⁻⁹ M AHK-Cu. No vehicle or comparator compound dose details beyond the molar range are specified in the abstract.
Results
AHK-Cu across 10⁻¹²–10⁻⁹ M stimulated elongation of human hair follicles in the ex vivo organ culture model. The same concentration range promoted proliferation of cultured DPCs in vitro. At 10⁻⁹ M, AHK-Cu reduced the number of apoptotic DPCs detected by Annexin V-FITC/PI flow cytometry, though this reduction did not reach statistical significance. Mechanistically, treatment with 10⁻⁹ M AHK-Cu elevated the Bcl-2/Bax ratio — a pro-survival shift — and reduced levels of the cleaved (active) forms of caspase-3 and PARP, indicating suppression of the intrinsic apoptotic cascade.
At 10⁻⁹ M AHK-Cu, the Bcl-2/Bax ratio was elevated and cleaved caspase-3 and PARP levels were reduced, pointing to meaningful anti-apoptotic activity in dermal papilla cells even where flow-cytometric apoptosis counts did not reach significance.
Key Findings
- AHK-Cu at 10⁻¹²–10⁻⁹ M stimulated elongation of human hair follicles ex vivo
- Same concentration range promoted dermal papilla cell (DPC) proliferation in vitro
- 10⁻⁹ M AHK-Cu elevated Bcl-2/Bax ratio, indicating a pro-survival shift in DPCs
- Cleaved caspase-3 and PARP levels were reduced at 10⁻⁹ M AHK-Cu
- Reduction in apoptotic DPC count was observed but did not reach statistical significance
Why It Matters
AHK-Cu joins a short list of peptide candidates with direct ex vivo human hair follicle evidence, which is a much higher evidentiary bar than rodent pelage assays. The dual action — promoting DPC proliferation while blunting caspase-3/PARP-mediated apoptosis — suggests the compound may help retain follicular cell mass, a mechanistic gap poorly addressed by current topical agents. Clinically, the active picomolar-to-nanomolar range (10⁻¹²–10⁻⁹ M) is notably low, implying that topical formulations could deliver relevant concentrations with minimal systemic exposure. Stacking considerations: given the known suppression of TGF-β1 by AHK-Cu in fibroblasts, combining it with agents that also target the androgen or TGF-β axis warrants further investigation, though no combination data exist yet.
